Study of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

Hernia Clinical Trial

Official title:

A Post-Market, Prospective, Multi-Center, Single-Arm Clinical Investigation of Phasix™ Mesh for VHWG Grade 3 Midline Hernia Repair

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02720042
• Other study ID #: DVL-HE-016
• Status: Completed
• Phase: N/A
• Start date: March 23, 2016
• Est. completion date: June 20, 2019

Study information

• Verified date: September 2020
• Source: C. R. Bard
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to collect additional data on safety and performance of Phasix™ Mesh in subjects requiring Ventral Hernia Working Group (VHWG) Grade 3 midline hernia repair.

Description:

Approximately 85 subjects, at approximately 12 sites across Europe will be enrolled and treated to study the use of Phasix™ Mesh. All treated subjects will be followed for 2 years post-implantation.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 84
• Est. completion date: June 20, 2019
• Est. primary completion date: July 31, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subject must be diagnosed with incisional midline hernia.

• Subject has a VHWG Grade 3 hernia (as defined in the protocol).

• Size of hernia = 10 cm2.

• Subject must be willing to undergo a planned retro-rectus hernia repair (onlay allowed as an exception when retro-rectus placement cannot be achieved; using absorbable suture) with or without Component Separation Technique.

Exclusion Criteria:

• Subject with > 4 previous repairs of the hernia under observation.

• Body Mass Index (BMI) > 35 kg/m2.

• The subject is on, or suspected to be placed on, chemotherapy medications during any part of the study.

• The subject has peritonitis.

• Known human immunodeficiency virus (HIV) infection (if documented in the subject's record).

• The subject has cirrhosis of the liver and/or ascites.

• Subject is American Society of Anesthesiology Class 4 or 5.

• Complete removal of existing mesh from a prior hernia repair (in the same affected area) is not possible.

• The hernia repair requires more than a single piece mesh (with adequate overlap beyond the margins of the defect on all sides).

• Subject has intact permanent mesh adjacent to the current hernia to be repaired.

• Subject's hernia repair requires intraabdominal mesh placement.

• Surgical technique requires surgical bridge repair as the sole repair.

• Subject has any condition that, in the opinion of the Investigator, would preclude the use of the study device, or preclude the subject from completing the follow-up requirements.

• Subject is pregnant or has plans to become pregnant during the study period or is currently breastfeeding.

• Subject has an alcohol/substance abuse problem or has had a relapse within 12 months of the screening visit.

• Subject was involved in another interventional clinical study in the last 30 days prior to Informed Consent Form (ICF) signature.

• Subject is part of the site personnel directly involved with this study.

• Subject has a life expectancy of less than 2 years at the time of enrollment.

• Subject has a known sensitivity to Phasix™ Mesh or component materials (patients with known allergies to tetracycline hydrochloride or kanamycin sulfate should be avoided).

Related Conditions & MeSH terms

• Hernia
• Hernia, Abdominal
• Hernia, Incisional
• Incisional Hernia

Intervention

Device:
• Phasix™ Mesh
A resorbable mesh prepared from poly-4-hydroxybutyrate (P4HB)

Locations

Country	Name	City	State
Austria	Wilhelminenspital	Vienna
Belgium	Imelda Ziekenhuis	Bonheiden
Belgium	UZ Gent	Gent
Belgium	UZ Leuven (Gasthuisberg)	Leuven
Denmark	Bispebjerg Hospital	Copenhagen
France	Centre Hospitalier Régional Universitaire de Lille	Lille
France	APHP Hôpital Cochin	Paris
Germany	Vivantes Hospital	Berlin
Germany	Day Surgery and Hernia Center	Cottbus	Brandenburg
Germany	Klinikum der Johann Wolfgang Goethe-Universität	Frankfurt
Italy	Policlinico Umberto I	Roma
Netherlands	IJsselland Ziekenhuis	Capelle Aan Den IJssel
Netherlands	Elkerliek Ziekenhuis	Helmond
Netherlands	Isala	Zwolle
United Kingdom	University College London Hospitals NHS Trust	London

Sponsors (1)

Lead Sponsor	Collaborator
C. R. Bard

Countries where clinical trial is conducted

Austria,  Belgium,  Denmark,  France,  Germany,  Italy,  Netherlands,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With One or More Surgical Site Occurrence Within 3 Months of Index Procedure	Proportions of subjects with Surgical Site Occurrences, which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 3 months. For analysis purposes, the aggregate Surgical Site Occurrence is defined as follows: "The question	3 Months
Secondary	Number of Participants With One or More Surgical Site Occurrence Within 24 Months of Index Procedure	Proportions of subjects with Surgical Site Occurrences, which are defined as hematoma, seroma, surgical site infection, wound dehiscence, skin necrosis and fistula requiring intervention. Occurrences at the surgical site will be assessed by physical examination at each study visit through 3 months. For analysis purposes, the aggregate Surgical Site Occurrence is defined as follows: "The question	24 Months
Secondary	Number of Participants With a Hernia Recurrence	Proportion of subjects with hernia recurrence. Hernia recurrence rates will be assessed by physical examination (or if standard of care via CT/MRI or ultrasonography) at each study visit through 24 months. A recurrent hernia will be defined as any hernia identified or confirmed by the investigator, during any study follow-up visit, in approximately the same position as the hernia repaired in the study procedure.	24 Months
Secondary	Number of Participants With One or More Surgical Site Infection	Proportion of subjects with surgical site infections. Infections at the surgical site will be assessed by physical examination at each study visit through 24 months. If an infection is suspected, a routine culture, obtained via each site's standard protocol, should be obtained to determine cell count and type (i.e. yeast, gram positive or gram negative bacteria, or other). If genus and species of the culture are identified as part of the routine practice at the site, that information should be recorded. Classification will follow the US Centers of Disease Control and Prevention (CDC) guidelines for superficial, deep and organ/space surgical site infections.	24 Months
Secondary	Mean Change in Pain Between Baseline (Pre-Index Procedure) and 24 Months Post-Index Procedure, as Measured by a 10.0 cm Visual Analogue Scale	Mean change in self-reported pain measured on a Visual Analog Scale between Baseline and 24-month follow up. Scores are measured on a 10.0 cm line, lower values correspond with low pain perception. The outcome measure is presented as the absolute difference between the pain perception at Baseline and the pain perception at 24-month follow up. A negative score means a decrease in pain perception.	24 Months
Secondary	Number of Participants With One or More Device-related Adverse Event	Incidence Device-related Adverse Events: number of subjects with one or more possibly or definitely device-related Adverse Event.	24 Months
Secondary	Number of Participants Requiring Reoperation Due to Index Hernia Repair	Rate of reoperation due to the index hernia repair: the proportion of subjects with post-procedure reoperation due to the index hernia repair.	24 Months
Secondary	Mean Patient Reported Outcomes on Quality of Life Parameters as Measured by the Carolinas Comfort Scale (CCS) at 1, 3, 12 and 24 Months Post-Index Procedure	Each scale score (sensation of mesh, pain or movement limitations) ranges from 0-5 and is the average across the domains. The Total CCS Score ranges from 0-5 and is the average of the 3 scale scores. Low scores represent fewer symptoms or difficulties.; Absolute values of the Total CCS Score at 1-Month follow-up, at 3-Month follow-up, at 12-Month follow-up and at 24-Month follow up are reported.; The absolute value at Baseline, or a change in self-reported quality of life measured by Carolinas Comfort Scale® cannot be reported, as subjects had incorrectly answered the questions on Sensation of Mesh at Baseline where no Phasix Mesh was yet implanted, thereby creating a bias in the results.	24 Months
Secondary	Mean Change in Quality of Life Assessments as Measured by the EQ-5D Between Baseline (Pre-Index Procedure) and 24 Months Post-Index Procedure	Change in self-reported quality of life measured by EuroQol-5 Dimensions (EQ-5D™). Each of the 5 dimensions (mobility, self-care, usual activities, pain/discomfort and anxiety/depression) has 3 levels (no problems, some problems and extreme problems). The data is converted into a summary index number between 0 and 1, whereby 1 corresponds with the highest perception of Quality of Life. The outcome measure reports the absolute change from Baseline until 24-months follow up. A positive value corresponds with an increase in Quality of Life.	24 Months
Secondary	Mean Surgical Procedure Time of the Index Procedure as Measured From Incision to Closure	Surgical procedure time as measured from incision to closure (skin to skin)	1 day
Secondary	Mean Time Until Participants Were Able to Return to Work	The number of days until subject returned to work, calculated as the date when employed subjects were able to fully get back to work minus the date of surgery.	24 Months
Secondary	Mean Length of Hospital Stay Related to Index Procedure	The length of hospital stay for the index procedure is calculated as the date of hospital discharge minus the date of hospital admission. Days in intensive care unit, days in step down unit (medium care) and days in the ward will be summarized as well.	1 Month